HemaCare Co. (OTCMKTS:HEMA) rose 0.4% on Wednesday . The company traded as high as $19.68 and last traded at $19.68, approximately 11,973 shares changed hands during mid-day trading. An increase of 167% from the average daily volume of 4,484 shares. The stock had previously closed at $19.60.
Separately, Zacks Investment Research lowered HemaCare from a “buy” rating to a “hold” rating in a research report on Wednesday, October 23rd.
The business has a 50-day simple moving average of $19.41 and a 200 day simple moving average of $15.29.
HemaCare Corporation provides human-derived primary blood cells and tissues for biomedical research, and supporting cell therapy clinical trials and commercialization with apheresis collections in the United States. The company specializes in the customized collection, isolation, and testing of primary human blood cells and other biological products for research protocols and cellular therapy.
See Also: Short Selling
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.